In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Shifting Exposure From Growth to Value Note: This is an abbreviated report (no detailed Sector comments or Russell grids). We will return to our normal report structure next week. While the market remains in consolidation/pullback mode and we are not out of the woods, it is possible that further downside is limited from here on the S&P 500. Since late-February, we have discussed important gap support from 2/22/24 at 4983-5050 on the S&P 500, and that as long as the S&P 500 is above 4983 that b...
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below. ...
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS). Michael S. Weiss, Chief Executive Officer and Chairman of ...
Norwegian Cruise Line Holdings to Hold Conference Call on First Quarter 2024 Financial Results MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings” or the “Company”) announced today it will report first quarter 2024 financial results on Wednesday, May 1, 2024 at 7:30 a.m. Eastern Time with a conference call and webcast to discuss results at 10:00 a.m. Eastern Time. The conference call will be webcast via the Company’s Investor Relations website, . A replay of the webcast will be av...
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. A link to the data presented yesterday is included below. Two additional pre...
Moody's Ratings today affirmed PENN Entertainment, Inc.'s ("PENN") B1 Corporate Family Rating and B1-PD Probability of Default Rating. Moody's Ratings also affirmed the Ba3 rating on PENN's senior secured revolving credit facility, senior secured term loan A, and secured term loan B, as well as the ...
Moody's Ratings today affirmed PENN Entertainment, Inc.'s ("PENN") B1 Corporate Family Rating and B1-PD Probability of Default Rating. Moody's Ratings also affirmed the Ba3 rating on PENN's senior secured revolving credit facility, senior secured term loan A, and secured term loan B, as well as the ...
Norwegian Cruise Line Holdings Unveils Bold New Vision for the Future with Strategic Long Term Fleet Expansion and Enhanced Private Island Development Plan includes next generation vessels for Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises to be built by Fincantieri, along with infrastructure enhancements for Great Stirrup Cay, all while continuing its disciplined multi-year de-leveraging plan MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings”, “Norwegian”...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.